The University of Wisconsin Carbone Cancer Center in Madison has enrolled the first patient in a Phase 1-2 PET imaging trial of I-124-CLR1404 (LIGHT, Novelos Therapeutics), a cancer-targeted PET imaging agent, in patients with advanced non-small cell lung cancer (NSCLC).
Positive findings at preoperative PET in the mediastinum appear to have prognostic implications for non-small-cell lung cancer despite histologically negative mediastinal lymph nodes, according to a single-center study published in the October issue of Radiology.
Image-guided thermal ablation of lung malignancies is on the rise and appears to offer a safe choice for a subset of non-surgical candidates. However, additional clinical studies are needed to demonstrate the efficacy of the procedure in comparison with other treatments, according to a review article published in the September issue of
Radiology.
Cetuximab combined with chemoradiotherapy increases lung cancer survival while inducing side effects comparable to chemotherapy alone, offering promising phase II results that clinicians hope will roll over to an ongoing phase III trial.
RSS 
